ClinicalTrials.gov
public full text
Public Domain
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS#1114414
- NT-I7 for Kaposi Sarcoma in Patients With or Without HIV#807549
- Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma#1162470
- When Unilateral Leg Swelling is Not Deep Vein Thrombosis: A Case of Disseminated Kaposi Sarcoma Revealing Advanced Human Immunodeficiency Virus#465419
- Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma#877132
Record · ID 825405
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive